Navigation Links
CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
Date:6/1/2008

- Data presented at the 2008 ASCO Annual Meeting -

- Conference call to be hosted Wednesday, June 4 at 9:00 a.m. EDT to

discuss results -

BRANFORD, Conn., June 1 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) today presented encouraging results from the ongoing Phase I/II study of CR011-vcMMAE for the treatment of unresectable Stage III or Stage IV melanoma. The results were presented by Dr. Patrick Hwu, Co-Principal Investigator, and Professor, Chairman, Dept. of Melanoma Medical Oncology at The University of Texas, M.D. Anderson Cancer Center.

"In this heavily pretreated group of patients with primarily Stage IV disease, the observation of dose-dependent objective responses, tumor shrinkage, and encouraging early progression-free rate at 12 weeks at doses in the anticipated active range, leads us to believe that CR011-vcMMAE could be a potentially useful treatment for patients with advanced melanoma," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "Based on these promising results in melanoma we have expanded the CR011-vcMMAE development program to include a Phase II trial in metastatic breast cancer, and are also exploring additional doses and schedules to further optimize the activity of this antibody-drug conjugate."

As of April 4, 2008, forty patients were treated in this first-in-man Phase I/II study including a total of 32 patients in the Phase I dose-escalation portion of the trial that aimed to identify the safety and maximum tolerated dose (MTD) of CR011-vcMMAE and 8 patients in the ongoing Phase II portion of the study. During Phase I, doses of CR011-vcMMAE between 0.03 mg/kg to 2.63 mg/kg were evaluat
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 ... announced the addition of the "Global Smart ... report to their offering.      (Logo: ... Wearable Healthcare Devices and Services market to grow ... 2015-2019 The report covers the present ...
(Date:3/26/2015)... 26, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" ... patent acceptance notice from the Israeli patent office with ... or reduce tissue damage caused by an increase in ... vessels are opened after a blockage causing a heart ... Damage can be caused to the heart ...
(Date:3/26/2015)... N.J. , March 26, 2015  Becton, Dickinson ... that it will commence offers to exchange all validly ... by CareFusion Corporation, a wholly owned subsidiary of BD, ... in the table below. A Registration Statement on Form ... the New Notes was filed with the Securities and ...
Breaking Medicine Technology:Global Smart Wearable Healthcare Devices and Services Market 2015-2019 WITH Apple, At&T, Ee, Google, Samsung, Sprint, Telefonica & T-Mobile Dominating 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5
... samples to be used to identify molecular,signature of ... ALS Therapy,Development Institute (ALS TDI) announced today ... samples collected through an expanded network,of clinical partnerships. ... effort to indentify the altered expression of genes,and ...
... Vical Incorporated,(Nasdaq: VICL ) today ... a leading European medical university, and the ... governmental expert agency, to,evaluate Vical,s Vaxfectin(R) adjuvant ... Medical Technologies Inc.,OTCBB:BJCT) for a multivalent preventive ...
Cached Medicine Technology:ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5
(Date:3/26/2015)... MALVERN, PA (PRWEB) March 26, 2015 ... leading providers of continuing medical education, the ... for Culinary Medicine at Tulane University are ... in Culinary Medicine. The interdisciplinary program ... Specialist (CCMS) credential, is designed for physicians, nurse ...
(Date:3/26/2015)... “The SWEET Act is an important step to ... and help parents who are working to reduce sugar in ... to support public health, and we will continue to stand ... of all families,” said Dr. Jane Delgado President and CEO ... of the Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman Rosa ...
(Date:3/26/2015)... Saving Moses is a global humanitarian ... needed but least available. As one of their staple ... in the Benguela province of Angola to treat babies ... visit to their clinics, staff employed the art of ... babies in a nation the The New York Times ...
(Date:3/26/2015)... Frencisco, CA (PRWEB) March 26, 2015 ... Center are proud to announce expanded offerings for Bay ... San Francisco Dental Implant Center has long been a ... have expanded its offerings to meet the strong demand ... in our reputation as a top-rated dental implant facility ...
(Date:3/26/2015)... San Juan Capistrano, Calif. (PRWEB) March 26, 2015 ... monitoring equipment and repairs, is pleased to be featured ... the Discovery Channel on March 18, 2015. The ... status, and it is live on the Pacific Medical ... families that face life threatening emergencies, it is reassuring ...
Breaking Medicine News(10 mins):Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Saving Moses Utilized Photography in an Effort to Engage Mothers and Their Babies on a Recent Visit to Angola 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3
... But Canadian study finds increase in non-serious side effects ... contain compounds called cannabinoids from the marijuana plant don,t ... associated with an increase in some non-serious side effects, ... in Montreal and the University of British Columbia (UBC) ...
... its wholly-owned subsidiary Embryome Sciences, Inc. announced ... International Embryome Initiative, an international collaboration with ... first systematic map of all the cell ... In a paper published today titled “The ...
... cellular ... analysis capabilities, ... a leader in innovative solutions for drug discovery and ... (Sunnyvale, CA) for $13 million. The acquisition,of Blueshift Biotechnologies, ...
... latest,report by the American Lung Association, Lung Disease Data, ... death rates due to other,leading causes of death such ... pulmonary disease (COPD) is expected to,become the third leading ... Association publishes Lung Disease Data to serve as a,resource ...
... Accelera Recognised as Key Partner in the Development of ... treatment of African,trypanosomiasis, commonly known as "sleeping sickness", by ... business unit of,Nerviano Medical Sciences (NMS), is to be ... The award will be conferred today in New York, ...
... Community in Hydration and Sanitation, Sand Bag , ... ... students assisted Missouri community residents who were impacted by raging ... students ensured that Clarksville families were educated on proper sanitation, the ...
Cached Medicine News:Health News:Drugs With Marijuana Compounds Don't Boost Adverse Events 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 3Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 4Health News:MDS Analytical Technologies Acquires Blueshift Biotechnologies 2Health News:American Lung Association Report Finds Lung Disease Death Rates Increasing While Cancer, Heart Disease and Stroke Death Rates Are Decreasing 2Health News:American Lung Association Report Finds Lung Disease Death Rates Increasing While Cancer, Heart Disease and Stroke Death Rates Are Decreasing 3Health News:The "DNDi Project of the Year": The Development of Fexinidazole to Treat "Sleeping Sickness" 2Health News:Sanford-Brown College Students Help in Missouri Flood Relief 2
... is part of a series of modular systems ... from 3.5 to 8.0 mm. Matching a combination ... provides convenience and flexibility for the orthopaedic surgeon ... may be customized using two of three screw ...
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
... a complete system of surgical instruments and ... fusion surgery. The system was designed in ... research and engineering with advanced materials, techniques ... different, and because the anatomy of the ...
... The Retrograde Humeral Nail enables fixation ... shoulder symptoms that may be associated with ... enables proximal and distal interlocking using a ... for posterior-anterior interlocking with the patient in ...
Medicine Products: